Astrocyte-Specific Overexpression of Nrf2 Delays Motor Pathology and Synuclein Aggregation throughout the CNS in the Alpha-Synuclein Mutant (A53T) Mouse Model

Alpha synuclein (SYN) is a central player in the pathogenesis of sporadic and familial Parkinson's disease (PD). SYN aggregation and oxidative stress are associated and enhance each other's toxicity. It is unknown whether the redox-sensitive transcription factor nuclear factor erythroid 2-...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of neuroscience Vol. 32; no. 49; pp. 17775 - 17787
Main Authors Gan, Li, Vargas, Marcelo R., Johnson, Delinda A., Johnson, Jeffrey A.
Format Journal Article
LanguageEnglish
Published United States Society for Neuroscience 05.12.2012
Subjects
Online AccessGet full text
ISSN0270-6474
1529-2401
1529-2401
DOI10.1523/JNEUROSCI.3049-12.2012

Cover

More Information
Summary:Alpha synuclein (SYN) is a central player in the pathogenesis of sporadic and familial Parkinson's disease (PD). SYN aggregation and oxidative stress are associated and enhance each other's toxicity. It is unknown whether the redox-sensitive transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) plays a role against the toxicity of SYN. To examine this, mice selectively overexpressing Nrf2 in astrocytes (GFAP-Nrf2) were crossed with mice selectively expressing human mutant SYN (hSYN A53T ) in neurons. Increased astrocytic Nrf2 delayed the onset and extended the life span of the hSYN A53T mice. This correlated with increased motor neuron survival, reduced oxidative stress, and attenuated gliosis in the spinal cord, as well as a dramatic decrease in total hSYN A53T and phosphorylated (Ser129) hSYN A53T in Triton-insoluble aggregates. Furthermore, Nrf2 in astrocytes delayed chaperone-mediated autophagy and macroautophagy dysfunction observed in the hSYN A53T mice. Our data suggest that Nrf2 in astrocytes provides neuroprotection against hSYN A53T -mediated toxicity by promoting the degradation of hSYN A53T through the autophagy-lysosome pathway in vivo . Thus, activation of the Nrf2 pathway in astrocytes is a potential target to develop therapeutic strategies for treating pathologic synucleinopathies including PD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: L.G. and J.A.J. designed research; L.G., M.R.V., and D.A.J. performed research; M.R.V. and D.A.J. contributed unpublished reagents/analytic tools; L.G. and J.A.J. analyzed data; L.G. and J.A.J. wrote the paper.
M. R. Vargas' present address: Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, 29425.
ISSN:0270-6474
1529-2401
1529-2401
DOI:10.1523/JNEUROSCI.3049-12.2012